Entrada Therapeutics, Inc. - TRDA STOCK NEWS

Entrada Therapeutics (Nasdaq: TRDA) has shared promising non-human primate data for its lead candidate, ENTR-601-44, indicating a durability of response for 12 weeks in treating Duchenne muscular dystrophy (DMD). The company also introduced ENTR-701, targeted at myotonic dystrophy type 1 (DM1). Both candidates are set for Investigational New Drug applications: ENTR-601-44 in Q4 2022 and ENTR-701 in 2023. These advancements reinforce Entrada's commitment to developing intracellular therapeutics with potential for transformative patient outcomes.

Entrada Therapeutics (Nasdaq: TRDA) announced that CEO Dipal Doshi will present virtually at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will be accessible starting May 23, 2022, at 7:00 a.m. ET on the company's website. A replay will be available for 90 days after the event.

Entrada focuses on Endosomal Escape Vehicle (EEV™) therapeutics to deliver medicines intracellularly, particularly for conditions like Duchenne muscular dystrophy and myotonic dystrophy.

Entrada Therapeutics (Nasdaq: TRDA) reported financial results for the fourth quarter and full year ending December 31, 2021. The company secured approximately $209 million from its IPO and held $291.1 million in cash as of year-end. Planned developments include submitting an IND application for ENTR-601-44 targeting Duchenne muscular dystrophy in the second half of 2022. R&D expenses rose to $12.4 million for Q4 2021, with a net loss of $18.4 million. G&A expenses also increased significantly, reflecting higher personnel and professional fees.

Entrada Therapeutics (Nasdaq: TRDA) will have its CEO, Dipal Doshi, participate in the Neuromuscular Panel at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 9:10 a.m. ET. The event aims to discuss the company’s innovative therapeutics, specifically its Endosomal Escape Vehicle (EEV™) technology. A live webcast will be available on Entrada’s website, with a replay accessible for 90 days post-event. The company focuses on developing treatments for neuromuscular diseases and has a robust portfolio targeting conditions like Duchenne muscular dystrophy.

Entrada Therapeutics (Nasdaq: TRDA) has appointed Jared Cohen, PhD, JD, as General Counsel, effective immediately. This move is a recognition of his significant contributions since joining the company, particularly in legal and compliance functions during recent financings. Dr. Cohen, who has nearly 20 years of experience in the healthcare sector, previously held leadership positions at several biopharmaceutical organizations. His appointment is expected to guide Entrada through its next phase of growth in developing its innovative Endosomal Escape Vehicle (EEV™) therapeutics.

Entrada Therapeutics (Nasdaq: TRDA) announced its addition to the Russell 2000® and Russell 3000® Indexes, effective December 20, 2021. This inclusion follows the company's successful IPO in November 2021 and aims to enhance market awareness for its Endosomal Escape Vehicle (EEV™) therapeutics. The Russell indexes are benchmarks for investment strategies, with about $10.7 trillion in assets linked to them. This milestone is expected to broaden Entrada's visibility in the investment community, as it advances its EEV therapeutic candidates targeting previously inaccessible intracellular targets.

Entrada Therapeutics, Inc. (Nasdaq: TRDA) completed a successful upsized IPO, raising $208.7 million in November 2021, positioning the company for significant advancements. Financial results for Q3 2021 revealed cash and cash equivalents of $122.2 million, excluding IPO proceeds. R&D expenses rose to $10.5 million, driven by preclinical studies and higher personnel costs. G&A expenses also increased to $3.9 million, reflecting higher legal fees and personnel costs. The net loss for Q3 2021 was $14.4 million, compared to $7.0 million in Q3 2020, signaling increased operational investments.

Entrada Therapeutics (Nasdaq: TRDA) announced that CEO Dipal Doshi will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021, at 12:10 p.m. ET. The event aims to showcase Entrada's focus on creating Endosomal Escape Vehicle (EEV™) therapeutics to tackle previously unaddressed intracellular targets. A live webcast of the chat will be available on the company's website, followed by a 90-day replay. Entrada is developing EEV therapeutics to enhance treatment for various diseases, including Duchenne muscular dystrophy.

Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced the closing of its initial public offering, successfully selling 9,075,000 shares at $20.00 each, raising approximately $181.5 million. All shares were offered by Entrada. The offering commenced trading on October 29, 2021. Underwriters also hold an option for an additional 1,361,250 shares within 30 days. Goldman Sachs, Cowen, and Evercore acted as joint book-running managers for this offering. The company focuses on innovative Endosomal Escape Vehicle (EEV™) therapeutics targeting previously inaccessible intracellular diseases.